Zealand Pharma A/S (ZEAL) 2016年年度报告「NASDAQ」.pdf

1、Zealand Pharma A/SCompany reg.no.20045078Annual Report2016Entering a new eraWe are a Danish biotech company discovering and developing novel peptide-based medicines.We are passionate about improving patients lives and committed to delivering value for all our stakeholders.We intend to be a world lea

2、der in medicines focusing on specialty gastrointestinal and metabolic diseases2Zealand Pharma A/SAnnual Report 2016Management reviewContentsFinancial statementsIncome statement 43Statement of comprehensive income 43Statement of financialposition 44Statement of cash flows 45Statement of changesin equ

3、ity 46Notes 47Statement of the Board of Directors and Executive Management 79Independent auditors report 80Corporate mattersCorporate governance 28Risk management and internalcontrol 30Corporate social responsibility(CSR)32Human resources 33Financial review 34Shareholder information 36Board of Direc

4、tors 38Senior Management 40Own clinical pipelineProduct pipeline 19Disease focus 20Glepaglutide for short bowel syndrome 21Dasiglucagon for acute,severe hypoglycemia 23Dasiglucagon for type1diabetes care 25AboutIn brief 4Letter from the CEO 6Financial highlights 8Consolidated key figures 92016 key e

5、vents 10Financial statementsManagement reviewFront page:Louise from Molecular Pharmacology,working in one of Zealands laboratories.Strategy and partnershipsStrategy and roadmap 12Value creation 13Adlyxin/Lyxumia 14Soliqua 100/33/Suliqua 15Collaborations with Boehringer Ingelheim and Helsinn 16Buildi

6、ng the future pipeline 173Zealand Pharma A/SAnnual Report 2016Management reviewIn briefOur approach We build for success by maintaining a lean and agile organization and by partnering with the best in their fields,leading to greater efficiency and better results.We have a history of successful outli